Biotech RadarJobs updated

COMPANY

Arialys Therapeutics

HQ: La Jolla, CA source · arialysrx.com ↗ · West Coast

Clinical Phase 1

Arialys Therapeutics is developing new precision medicines to specifically block the effect of pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. From company website Source · Oct 12, 2026

Keywords: Autoimmune Encephalitis Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder) ART5803

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

  1. Trial start 1: Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants source ↗
  2. Trial start 1: Phase 1 Study of ART5803 in Healthy Participants source ↗

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06753955Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants1CompletedFeb 25, 2025Jul 2, 2025 (actual)
NCT06575153Phase 1 Study of ART5803 in Healthy Participants1CompletedSep 19, 2024Sep 11, 2025 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback